BCD Innovations, Inc. develops novel methods for the prediction, detection, and treatment of cancer. We are dedicated to the commercialization of transformative approaches using patented genetic analysis technologies. BCD’s Plain Yard Test™, a highly accurate molecular test for the diagnosis of bladder cancer is expected to launch in the market in 2018.
The Plain Yard test uses patented microsatellite analysis technology (MSA) to analyze 15 DNA loci in regions of DNA that were previously thought to be “junk” DNA (a microsatellite). It is now known that mutations in these microsatellite regions are markers for malignancy. Microsatellite DNA in cells collected from the urine sediment is compared to a patient’s normal microsatellite DNA collected from a buccal swab. A proprietary computer-based algorithm based on a comparative analysis between these two sources allows for the detection of cancer with a very high sensitivity and specificity.
The biochips market is segmented into DNA chips, lab-on-a-chip, protein chips, and other arrays. The other arrays segment includes cell arrays and tissue arrays. Based on applications, the DNA chips segment is categorized into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, agricultural biotechnology, drug discovery, and other applications (microbial genotyping, proteomics, toxicogenomics, screening and monitoring of patient data in clinical trials, and environmental biology). Based on applications, the lab-on-a-chip segment is classified into genomics, proteomics, drug discovery, IVD & POC clinical diagnostics, and other applications (biodefense, food pathogen identification, and environmental contamination).